Kalaris Therapeutics, Inc. (KLRS) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

High Risk
Significant dilution risk
Last updated: May 12, 2026

Risk Assessment Details

Potential Dilution: 297.57% of current shares
Recent Dilution: 299.84% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
24M
Potential Supply
71M
Additional shares possible
Splits
None
Past 2 years

Summary

KLRS currently has 23.7M outstanding shares. with significant dilution risk as 70.6M authorized shares could dilute existing holders by 297.6%. The company has significantly diluted shareholders by 299.84% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 12, 2026

10-Q filing | 23.7M shares outstanding

24M 71M
Apr 03, 2026

S-3 filing: The company intends to offer and sell debt securities, common stock, preferred stock and subscription rights from time to time in one or more offerings of up to $350,000,000 in aggregate offering price.

23M 71M
Apr 03, 2026

S-3 filing: This prospectus relates to the resale from time to time of up to 5,000,000 shares of common stock of Kalaris Therapeutics, Inc. by the selling stockholders.

23M 53M
Mar 17, 2026

10-K filing | 22.9M shares outstanding

23M 48M
Aug 13, 2025

10-Q filing | 18.7M shares outstanding

19M 48M
May 14, 2025

10-Q filing | 18.7M shares outstanding

19M 48M
Mar 07, 2025

10-K filing | 5.0M shares outstanding

5M 48M
Nov 12, 2024

10-Q filing | 115.4M shares outstanding

120M 48M
Aug 09, 2024

10-Q filing | 115.1M shares outstanding

120M 48M
May 13, 2024

10-Q filing | 114.7M shares outstanding

110M 48M
Mar 15, 2024

10-K filing | 104.1M shares outstanding

100M 48M
Nov 02, 2023

10-Q filing | 113.9M shares outstanding

110M 48M
Aug 03, 2023

10-Q filing | 113.9M shares outstanding

110M 48M
May 04, 2023

10-Q filing | 93.3M shares outstanding

93M 48M
Feb 15, 2023

S-3 filing: This prospectus relates to the proposed resale, from time to time, by the selling stockholders identified in this prospectus of up to 31,359,683 shares of our common stock, par value $0.0001 per share.

93M 48M
Feb 15, 2023

10-K filing | 93.5M shares outstanding

93M 48M
Nov 03, 2022

10-Q filing | 84.9M shares outstanding

85M 17M
Aug 04, 2022

10-Q filing | 93.1M shares outstanding

93M 17M
May 05, 2022

10-Q filing | 65.4M shares outstanding

65M 17M
Feb 10, 2022

10-K filing | 65.3M shares outstanding

65M 17M
Feb 10, 2022

POS AM filing: The filing is a POS AM for a shelf offering of common stock, preferred stock, and debt securities, with a total aggregate amount not to exceed $250,000,000.

65M 17M
Nov 05, 2021

10-Q filing | 65.1M shares outstanding

65M 17M
Aug 06, 2021

10-Q filing | 65.1M shares outstanding

65M 17M
May 06, 2021

10-Q filing | 65.1M shares outstanding

65M 17M
Feb 12, 2021

10-K filing | 65.1M shares outstanding

65M 17M
Nov 10, 2020

10-Q filing | 65.1M shares outstanding

65M 17M
Sep 02, 2020

10-Q filing | 21.6M shares outstanding

22M 17M
Jul 23, 2020

S-1/A filing: This S-1/A filing from 2020-07-23 describes an initial public offering of common stock at $17.00 per share, with 14,750,000 shares offered and an option for underwriters to purchase an additional 2,212,500 shares.

61M 17M
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime